About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.

GEUS-CLL

The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

Aniling at the DxPx conference in Munich

Aniling is attending the DxPx conference in Munich! Our experience at this event, including one-to-one meetings, has provided us with a great opportunity to connect with industry leaders and investors …